Search Bar & Filters
Found 34 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.
Actively Recruiting
This research aims to collect and evaluate safety and effectiveness information about Jyseleca tablet Filgotinib Maleate 100 mg and 200 mg in Korean participants using it in real-world conditions. The study focuses on monitoring serious and non-serious adverse events and drug reactions, including unexpected ones, as well as changes in disease activity scores related to rheumatoid arthritis and ulcerative colitis. Participants prescribed Jyseleca according to Korean approved therapeutic indications will be observed without additional intervention. They will be followed for up to 24 weeks or until they stop treatment due to adverse events or other reasons. The study includes adults with rheumatoid arthritis or ulcerative colitis who have not responded well or are intolerant to prior treatments. During the study, researchers will track adverse events and reactions from enrollment through 24 weeks. They will also measure changes in disease activity scores at baseline, week 12, and week 24. Participants will have regular monitoring visits as part of their usual care, with data collected about safety and treatment effects. The total participation time is up to 24 weeks.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes zipalertinib in adults with locally advanced or metastatic Non-Small Cell Lung Cancer NSCLC that has specific mutations in the EGFR gene called exon 20 insertions and other uncommon mutations. This Phase 2b study includes participants with different prior treatment histories and brain metastases to understand how zipalertinib works in these groups. The study also explores possible interactions between zipalertinib and other drugs and aims to identify the best dose for treatment. Participants are divided into four main groups based on their mutation type and treatment history. They receive zipalertinib orally twice daily continuously until disease progression or other reasons for stopping. Additional substudies enroll participants to evaluate drug interactions using special probe medications and to optimize dosing by randomly assigning participants to different dose groups. The dosing cycles last 21 days, and treatments continue as long as criteria are met. Throughout the study, participants undergo regular assessments including tumor measurements, brain imaging for those with brain metastases, heart monitoring with ECG and scans, laboratory tests, and evaluation of side effects. Researchers measure outcomes such as tumor response rates, disease control, progression-free survival, and overall survival for up to two years. Safety is closely monitored by tracking adverse events and changes in vital signs and organ function. Participants remain under observation during treatment and follow-up periods until study completion.
Actively Recruiting
Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.
Actively Recruiting
Researchers are evaluating zipalertinib, a new EGFR tyrosine kinase inhibitor TKI, compared to a placebo in people with early stage non-small cell lung cancer NSCLC who have uncommon EGFR mutations and have had their tumors completely surgically removed. The study focuses on participants with specific uncommon EGFR mutations, including exon 20 insertions and others in exons 18-21, aiming to understand the treatments impact on disease-free survival after surgery. Participants are randomly assigned to receive either zipalertinib or a matching placebo, both taken orally twice daily. Treatment continues until certain criteria for stopping are met. An independent committee will monitor safety during the study. The study plans to include about 360 participants and will last up to 5 years for measuring outcomes. Throughout the trial, participants will be closely monitored with brain imaging before starting treatment to ensure no brain metastases. Researchers will assess disease-free survival as their main outcome over up to 5 years, along with overall survival and quality of life measures. Safety will be evaluated through tracking adverse events, lab tests, vital signs, heart function via ECG and scans, and quality of life questionnaires. Participants will have regular visits for treatment and assessment over the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.
1-10 of 34
1